Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
252 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atherosclerosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2016, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape. Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 43 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 25 and 4 molecules, respectively.Atherosclerosis. Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 6 Atherosclerosis Overview 7 Therapeutics Development 8 Atherosclerosis - Therapeutics under Development by Companies 10 Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 13 Atherosclerosis - Pipeline Products Glance 15 Atherosclerosis - Products under Development by Companies 18 Atherosclerosis - Products under Investigation by Universities/Institutes 22 Atherosclerosis - Companies Involved in Therapeutics Development 24 Atherosclerosis - Therapeutics Assessment 63 Drug Profiles 77 Atherosclerosis - Dormant Projects 210 Atherosclerosis - Discontinued Products 222 Atherosclerosis - Product Development Milestones 225 Appendix 241
List of Tables Number of Products under Development for Atherosclerosis, H2 2016 18 Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2016 19 Number of Products under Development by Companies, H2 2016 20 Number of Products under Development by Companies, H2 2016 (Contd..1) 21 Number of Products under Development by Companies, H2 2016 (Contd..2) 22 Number of Products under Investigation by Universities/Institutes, H2 2016 24 Comparative Analysis by Late Stage Development, H2 2016 25 Comparative Analysis by Clinical Stage Development, H2 2016 26 Comparative Analysis by Early Stage Development, H2 2016 27 Products under Development by Companies, H2 2016 28 Products under Development by Companies, H2 2016 (Contd..1) 29 Products under Development by Companies, H2 2016 (Contd..2) 30 Products under Development by Companies, H2 2016 (Contd..3) 31 Products under Investigation by Universities/Institutes, H2 2016 32 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 33 Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 34 Atherosclerosis - Pipeline by advanceCor GmbH, H2 2016 35 Atherosclerosis - Pipeline by AFFiRiS AG, H2 2016 36 Atherosclerosis - Pipeline by Akcea Therapeutics Inc, H2 2016 37 Atherosclerosis - Pipeline by Amgen Inc., H2 2016 38 Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 39 Atherosclerosis - Pipeline by ARMO Biosciences, Inc., H2 2016 40 Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H2 2016 41 Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2016 42 Atherosclerosis - Pipeline by Cardax, Inc., H2 2016 43 Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H2 2016 44 Atherosclerosis - Pipeline by ChemoCentryx, Inc., H2 2016 45 Atherosclerosis - Pipeline by CohBar, Inc., H2 2016 46 Atherosclerosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 47 Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 48 Atherosclerosis - Pipeline by DoNatur GmbH, H2 2016 49 Atherosclerosis - Pipeline by Dybly AG, H2 2016 50 Atherosclerosis - Pipeline by GenKyoTex S.A., H2 2016 51 Atherosclerosis - Pipeline by HitGen LTD, H2 2016 52 Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H2 2016 53 Atherosclerosis - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 54 Atherosclerosis - Pipeline by KineMed, Inc., H2 2016 55 Atherosclerosis - Pipeline by Kowa Company, Ltd., H2 2016 56 Atherosclerosis - Pipeline by La Jolla Pharmaceutical Company, H2 2016 57 Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016 58 Atherosclerosis - Pipeline by LipimetiX Development Inc, H2 2016 59 Atherosclerosis - Pipeline by Merck & Co., Inc., H2 2016 60 Atherosclerosis - Pipeline by Omeros Corporation, H2 2016 61 Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 62 Atherosclerosis - Pipeline by Resverlogix Corp., H2 2016 63 Atherosclerosis - Pipeline by The Medicines Company, H2 2016 64 Atherosclerosis - Pipeline by Therapix Biosciences Ltd., H2 2016 65 Atherosclerosis - Pipeline by Tolerys SA, H2 2016 66 Atherosclerosis - Pipeline by Unity Biotechnology, Inc., H2 2016 67 Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H2 2016 68 Atherosclerosis - Pipeline by Vericel Corporation, H2 2016 69 Atherosclerosis - Pipeline by Vicore Pharma AB, H2 2016 70 Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 71 Atherosclerosis - Pipeline by XBiotech Inc, H2 2016 72 Assessment by Monotherapy Products, H2 2016 73 Assessment by Combination Products, H2 2016 74 Number of Products by Stage and Target, H2 2016 76 Number of Products by Stage and Mechanism of Action, H2 2016 80 Number of Products by Stage and Route of Administration, H2 2016 84 Number of Products by Stage and Molecule Type, H2 2016 86 Atherosclerosis - Dormant Projects, H2 2016 220 Atherosclerosis - Dormant Projects (Contd..1), H2 2016 221 Atherosclerosis - Dormant Projects (Contd..2), H2 2016 222 Atherosclerosis - Dormant Projects (Contd..3), H2 2016 223 Atherosclerosis - Dormant Projects (Contd..4), H2 2016 224 Atherosclerosis - Dormant Projects (Contd..5), H2 2016 225 Atherosclerosis - Dormant Projects (Contd..6), H2 2016 226 Atherosclerosis - Dormant Projects (Contd..7), H2 2016 227 Atherosclerosis - Dormant Projects (Contd..8), H2 2016 228 Atherosclerosis - Dormant Projects (Contd..9), H2 2016 229 Atherosclerosis - Dormant Projects (Contd..10), H2 2016 230 Atherosclerosis - Dormant Projects (Contd..11), H2 2016 231 Atherosclerosis - Discontinued Products, H2 2016 232 Atherosclerosis - Discontinued Products (Contd..1), H2 2016 233 Atherosclerosis - Discontinued Products (Contd..2), H2 2016 234
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
